Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1391)	9/1/1998 7:30:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 2742

Another method being studied - which also addresses the safety issue - is to deliver IL-1b directly to the tumor. Wash. U. in St. Louis has published a fair amount of research in this area. Fascinating concept...they use a virus that selectively infects certain cancer tumors and doesn't infect healthy tissue. Using genetic techniques, they've encoded the IL-1b gene in the virus. After the virus is injected into the subject and infects the tumor, the virus pumps out IL-1b. Here are 3 abstracts that describe this work: Cancer J Sci Am 1996 Jan;2(1):21 In Vivo Murine Tumor Gene Delivery and Expression by Systemic Recombinant Vaccinia Virus Encoding Interleukin-1beta. Peplinski GR, Tsung K, Casey MJ, Meko JB, Fredrickson TN, Buller RM, Norton JA ncbi.nlm.nih.gov ---- Surgery 1995 Aug;118(2):185-190 In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Peplinski GR, Tsung K, Meko JB, Norton JA ncbi.nlm.nih.gov ---- Ann Surg Oncol 1995 Mar;2(2):151-159 Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA ncbi.nlm.nih.gov ---- Rudy